Listen up, pharma companies: The Securities and Exchange Commission sees a few places where you might get yourselves into sticky situations. But there's an easy way to avoid trouble, and that's to beef up compliance and disclosure.
Daktari Diagnostics closed a $15.5 million Series D round to support development of its innovative HIV test, chalking up a milestone in its quest to raise $30 million in funding for the product.
The da Vinci System for robotic surgery was originally developed as a prototype for remote battlefield surgery. Now Intuitive Surgical is returning to its military roots with a massive contract worth up to $430 million with the Defense Logistics Agency, which is part of the U.S. Department of Defense (DOD).
With oral rivals lurking for Rebif, the leading drug from Merck KGaA, the good news for the German pharma is that the news isn't that bad.
Stryker is signaling that it could hit the brakes on acquisitions after an aggressive string of at least a half-dozen purchases over the past few years, including the $1.7 billion purchase of robotic surgery player Mako Surgical in December 2013.
It's been less than a week since Mylan completed its deal with Abbott, scooping up a large chunk of the Illinois company's overseas generics business. But CEO Heather Bresch is already hinting at another big transaction.
Phase II results of the first clinical trial of a tau aggregation inhibitor for Alzheimer's disease were published last month in the Journal of Alzheimer's Disease, with Singapore-based TauRx Pharmaceuticals saying it was an important milestone as it moves to report top line results from a Phase III study in 2016.
The promises are coming home to roost for AstraZeneca CEO Pascal Soriot. Or so reports The Sunday Times, which says the U.K.-based company is once again under pressure to put Soriot's bonus pay on the line for the big goals he touted in defending against Pfizer's $100 billion takeover bid last year.
Cyfuse Biomedical is aiming to take its 3-D bioprinting technology to researchers around the world with its infusion of ¥1.4 billion ($12 million). Its bioprinter can be used to create tissue structures including cartilage and subchondral bone, tubular tissues such as blood vessels, digestive and urinary organs, and miniature livers.
Charles River Laboratories' longtime chief financial officer is stepping down in a planned retirement, giving the preclinical CRO a chance to further integrate its recent acquisitions and increase its focus on drug discovery.